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Background Inhaled antibiotics are standard of care for persons with cystic fibrosis (CF) and 
chronic Pseudomonas aeruginosa airway infection.  APT-1026 (levofloxacin inhalation solution, 
LIS) is fluoroquinolone in development.  We compared the safety and efficacy of LIS to 
tobramycin inhalation solution (TIS) in persons ≥12 years old with CF and chronic P. 
aeruginosa infection.  
Methods This multinational, randomized (2:1), non-inferiority study compared LIS and TIS over 
three 28-day on/off cycles.  Day 28 FEV1 % predicted change was the primary endpoint.  Time to 
exacerbation and patient-reported quality of life superiority were among secondary endpoints. 	  
Results Baseline demographics for 282 subjects were comparable. Non-inferiority was 
demonstrated (1.86% predicted mean FEV1 difference [95% CI −0.66 to 4.39%]).    LIS was 
well-tolerated, with dysguesia (taste distortion) the most frequent adverse event. 
Conclusions LIS is a safe and effective therapy for the management of CF patients with chronic 
P. aeruginosa.  	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INTRODUCTION 
Cystic fibrosis (CF) is characterized by chronic respiratory tract infection with multiple 
bacterial species, including Pseudomonas aeruginosa [1]. Chronic P. aeruginosa infection is 
associated with accelerated progression of lung disease, increased morbidity, and decreased 
survival [2-4].   
Inhaled antipseudomonal antibiotics are standard therapy to suppress infection, reduce 
risk of pulmonary exacerbations, improve quality of life, and preserve lung function in CF 
patients chronically infected with P. aeruginosa [5, 6].  Approved inhalational antibiotics for use 
in people with CF and chronic P. aeruginosa infection in the EU are tobramycin, colistimethate, 
and aztreonam, and in the US are tobramycin and aztreonam (e-supplement for approved product 
names).   
There is need for additional safe and effective inhaled antibiotics. The prevalence of 
chronic P. aeruginosa infection increases about 3% per year of age [7], with >70% chronically 
infected by adulthood [8].  As median predicted survival for CF has exceeded 40 years of age 
[8], adherence to consensus treatment guidelines [5, 6] will result in many patients being treated 
for decades with inhaled antibiotics.   
There is evidence that the FEV1 response to aerosolized tobramycin becomes attenuated 
in individuals with CF after exposure of more than 6 months [9, 10], a phenomenon that cannot 
be fully accounted for by selection of bacterial populations with decreased in vitro tobramycin 
susceptibilities [9]. Similar attenuation of efficacy may occur for other inhaled antibiotics [11].  
In addition, patient intolerance to some inhaled antibiotic formulations can be substantial [12, 
13]. Thus, there is a need for additional options, including alternate classes of antibiotics, to treat 
patients who are intolerant or have developed attenuated response and to allow for rotation of 
therapies to reduce the emergence of antimicrobial ineffectiveness [14] 
Fluoroquinolones have high potency and broad spectrum of bactericidal activity and so 
are attractive to develop as inhaled therapy for CF. APT-1026 (levofloxacin inhalation solution, 
LIS; also formerly known as MP-376) [15] is the first inhaled solution form of a fluoroquinolone 
intended for use in chronic maintenance therapy.  We describe the results of a phase 3 study 
designed to compare the efficacy and safety of LIS with tobramycin inhalation solution (TIS) 
when administered over multiple cycles in individuals with CF and chronic P. aeruginosa 
infection who had previously used inhaled tobramycin. 
 
METHODS 
Study Design 
This was a randomized, open-label, parallel group, active comparator trial conducted at 
125 CF centers in Europe, USA, and Israel.  Subjects were recruited between Feb 2011 and Aug 
2012.  Eligible patients were randomized 2:1 to three 28 days on/28 days off treatment cycles of 
LIS 240 mg (2.4 mL of a 100 mg of levofloxacin per ml as APT-1026) twice daily (BID) or TIS 
300 mg (5 mL) BID (TOBI®, Novartis Pharmaceuticals Corp.), with seven study visits 28 days 
apart (Figure 1). TIS was delivered with a PARI LC® Plus nebulizer with compressor as 
indicated in the prescribing information, and LIS was delivered with the PARI investigational 
eFlow® nebulizer.  Comparison to the approved licensed therapy and delivery device is mandated 
by the European Medicine Agency for approval of a new inhaled antibiotic for CF [16].   
Subjects and study coordinators were aware of the treatment assignment, but the site 
investigators and medical monitors remained blinded in order to minimize treatment bias during 
the study. 
The study was conducted in accordance with Good Clinical Practice, as recommended by 
the Declaration of Helsinki and the International Congress of Harmonization Guidelines, and the 
laws and regulations of each study site.  Institutional Review Boards and/or Ethics Committees 
approved the study for each site.  Patients provided written consent and/or parents provided 
consent for their children prior to undergoing study procedures.   
 
Participants 
Eligible patients were > 12 years of age with documented CF diagnosis, a forced 
expiratory volume in 1 second (FEV1) between 25 and 85 percent of their predicted values using 
Hankinson/NHANES III reference equations [17], chronic airways infection with P. aeruginosa, 
and had received at least three 28-day courses (> 84 days) of inhaled TIS over the 12 months 
prior to screening.  Prior TIS use was obtained by subject report and verified in the medical 
record.  Chronic P. aeruginosa infection was defined as report of a respiratory secretion culture 
positive for P. aeruginosa in the 12 months immediately prior to screening and a positive culture 
obtained at the screening visit 2-4 weeks prior to randomization.  Patients continued their routine 
respiratory care and medications.  Patients were not permitted to use other antipseudomonal 
antibiotics other than Study Drug unless deemed necessary by the Investigator to treat a 
suspected exacerbation. Detailed inclusion and exclusion criteria and randomization schema can 
be found in the e-supplement. 
 
Endpoints 
The primary efficacy endpoint was the relative change in FEV1 percent predicted from 
baseline to day 28.  The trial was designed as a non-inferiority study in accordance with 
guidance published by the EMA [16].  Additional endpoints included change in other spirometry 
parameters (FEV1 [L], FEF25-75 [L/s], FVC [L]) from baseline to day 28, time to pulmonary 
exacerbation, time to administration of antipseudomonal antibiotics other than Study Drug, 
change from baseline in CF Questionnaire-Revised (CFQ-R) respiratory symptom score [18], 
and change from baseline in sputum P. aeruginosa density (log10 colony-forming units (CFU) 
per gram sputum).  Lung function was compared between treatment groups after only 28 days to 
reduce the probability that concomitant antibiotic treatment for pulmonary exacerbation would 
confound analyses.  A pulmonary exacerbation was defined per protocol as a patient 
experiencing change in >4 of 12 concurrent signs or symptoms [19] regardless of decision to 
treat with an antibiotic.  An independent blinded adjudication board reviewed all instances in 
which patients received additional antipseudomonal antibiotics but did not meet the protocol 
definition of an acute exacerbation to determine if these treatments were associated with 
exacerbation (further description in e-supplement).  Adverse events and serious adverse events 
were captured from baseline to the final visit for each patient.  
Throat swabs or sputum were collected at all study visits (except visit 4/day 84) for 
selective bacterial culture and in vitro susceptibility testing by central laboratories.  Distinct P. 
aeruginosa morphotypes from patients were analyzed separately.  Bacterial densities in sputum 
specimens were determined by dilution plating.  
 
Statistics 
Statistical analysis was performed on the intention to treat (ITT) population consisting of 
all randomized patients. The primary non-inferiority endpoint of relative change in FEV1 percent 
predicted from baseline to day 28 was assessed with an analysis of covariance (ANCOVA) 
model including fixed effects for treatment group and the stratification binary variables of 
geographic region, age and baseline FEV1 percent predicted.  If the lower boundary of the 2-
sided 95% confidence interval (CI) for the treatment difference (LIS-TIS) was > −4% (pre-
specified non-inferiority margin), non-inferiority of LIS to TIS was concluded.  The prospective 
analysis plan dictated that if non-inferiority of LIS to TIS was demonstrated, a subsequent 
assessment of superiority was to be performed using a 2-sided test for difference at a 5% level of 
significance. 
The sample size was based on a 4% non-inferiority margin, an 18% SD in relative change 
from baseline in FEV1 percent predicted, and a 10% discontinuation rate over the first 28 days of 
the study.  A sample size of 267 patients randomized 2:1 to LIS and TIS, respectively, was 
selected to provide 90% power with a 2-sided 5% significance level based on an assumption that 
LIS was 4 percentage points better than TIS. 
Time to pulmonary exacerbation and time to treatment were analyzed by Cox 
proportional hazard method, with statistical significance determined by stratified log-rank test.  
There was no alpha adjustment for multiple testing for the other efficacy variables.  P-values 
from these tests were considered to be descriptive only and were evaluated for nominal 
significance only (i.e., whether ≤0.05).  Levofloxacin and tobramycin minimum inhibitory 
concentrations (MIC) were determined using broth dilution reference methods as published by 
the Clinical Laboratory Standards Institute (CLSI; REF-M100). Changes in the levofloxacin 
MIC were evaluated as the proportion of patients for which the levofloxacin MIC of their most 
resistant P. aeruginosa isolate changed by >2 fold (the limit of sensitivity of dilution testing) 
from baseline to the end of the study using a 2-sided Fisher’s exact test with a 5% significance 
level. [20]  
 
RESULTS 
Two hundred and eighty two patients were randomized in this study; 189 to receive LIS 
and 93 TIS, with 272 available for safety evaluation (Figure 2). Baseline characteristics of the 
groups were similar (Table 1).  At the randomization visit, P. aeruginosa and Staphylococcus 
aureus were isolated in 93% and 47% of patients, respectively (P. aeruginosa was isolated from 
all patients at the screening visit as per inclusion criterion).  There were no differences in 
baseline P. aeruginosa antibiotic susceptibility patterns between the two groups (e-supplement 
Table 1).  Concomitant medications were also similar between the two groups at baseline (e-
supplement Table 2). The median number of the inhaled antibiotic courses during the previous 
year was 5 and 44% of the enrolled patients had received 6 or more courses. 
 
Efficacy 
The study met the primary endpoint of non-inferiority in relative change in FEV1 percent 
predicted from day 0 to day 28.  The least squares (LS) mean between-group difference (LIS 
minus TIS) in FEV1 was 1.86% [95% CI -0.66 to 4.39%].  As non-inferiority of LIS was 
demonstrated, a subsequent assessment of superiority was performed.  The difference between 
the LS means for relative change in FEV1 percent predicted at day 28 between LIS and TIS was 
not statistically significant (2.24%, p=0.15; Figure 3; e-supplement Table 3).  A pre-planned 
analysis of categorical change in FEV1 percent predicted from baseline to day 28 showed 
improvement for 70% of patients receiving LIS compared to 53% of patients receiving TIS (p = 
0.02)  Similar trends were seen for FVC and FEF25-75 (e-supplement Tables 4 and 5).   
 
Time to exacerbation, additional antibiotic requirement and hospitalisation. 
The time to first exacerbation was not significantly different in the LIS group (median 
131 days) compared to the TIS group (median 90.5 days) (HR = 0.78; 95% CI: 0.57 to 1.07, 
p=0.15; Figure 4).  The median time to administration of antibiotics was 141 days for LIS and 
110 days for TIS(HR = 0.73; 95% CI: 0.53 to 1.01; p = 0.04 by stratified log rank test).  The 
proportion of patients hospitalized for a respiratory exacerbation over the 168 day study period 
was significantly lower in the LIS group than the TIS group (17.5% versus 28.0%, p = 0.04).   
 
CFQ-R Respiratory Domain 
Scores in the respiratory domain of the CFQ-R were similar at baseline. The LS means 
increased (i.e. improvement) in the LIS group and decreased in the TIS group at day 28 (3.19 
units, p = 0.05; e-supplement Figure 1). The results are similar between the two groups at the end 
of the study. 
 
Microbiology 
Both treatments reduced sputum P. aeruginosa density, with the magnitude of reduction 
greater for TIS than LIS, although the difference in change from baseline to day 28 was not 
significantly different (LS mean difference 0.44 log10 CFU/g; 95% CI -0.01 to 0.88).  P. 
aeruginosa densities increased during the subsequent period off treatment.  Over the course of 
the study, the proportion of patients who experienced a >2-fold increase in the levofloxacin MIC 
of their most levofloxacin-resistant P. aeruginosa isolate was similar in the two treatment groups 
(21% for LIS versus 17% for TIS; p = 0.5) (e-supplement Figure 2).  No significant emergence 
of other bacterial opportunists was observed in either treatment group during the study.  
 
Safety 
Discontinuations from the study (Figure 2) and the occurrence of treatment emergent 
adverse events (TEAEs; Table 2) were similar between the two groups.  Treatment emergent 
serious adverse events (SAEs) were reported for 22.0% of LIS and 32.2% of TIS patients. 
Excluding disease progression, treatment-emergent SAEs were reported for 7.7% of LIS patients 
and for 14.4% of TIS patients during the entire study.  There was a higher incidence of dysgeusia 
(taste distortion) in patients treated with LIS which accounted for the higher incidence of TEAEs 
reported in >5% of patients (Table 2).  During the treatment periods, the TEAEs other than 
dysgeusia that were reported for at least 5% more LIS patients than TIS patients were cough, 
increased sputum, paranasal sinus hypersecretion, and headache. Fluoroquinolone class effects 
associated with systemic administration, such as nausea, arthralgia and tendonitis were 
uncommon in this study. The incidence of arthralgia was low and similar between treatment 
groups (5.5% LIS, 5.6% TIS), and there were few cases of arthropathy and arthritis/osteoarthritis 
in the LIS group.  One LIS patient had an SAE of costochondritis that led to discontinuation of 
study drug and resolved after treatment. One LIS patient had symptoms consistent with 
tendonitis but there were no reports of tendon rupture. 
 
DISCUSSION 
The study demonstrates that LIS is not inferior to TIS in the treatment of patients with CF 
and chronic P. aeruginosa infection over 28 days.  Although the relative change in FEV1 percent 
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predicted at the end of each treatment period and the median time to first exacerbation favoured 
LIS compared to TIS (Figure 4), the differences between treatments were not significant.  
Additionally, respiratory symptoms measured by the CFQ-R respiratory domain improved for 
LIS patients compared to those receiving TIS (e-supplement Figure 1).   
TIS and LIS both reduced the sputum density of P. aeruginosa.  In addition, there were 
no clinically relevant changes in MICs to either drug during the study.  Previous placebo-
controlled studies of inhaled antibiotics have noted an association between mean antimicrobial 
effect (measured by change in bacterial density) and mean lung function benefit [9, 21].  
However, while there was a numerically greater mean antimicrobial effect among patients 
treated with TIS	   (Figure 3), there was a numerically greater change in FEV1 for those treated 
with LIS, suggesting there is not a simple relationship between the two measures.   
Pulmonary exacerbations are frequent and important events for patients with CF [22].  In 
this study, no difference was observed between the two groups in the occurrence of pulmonary 
exacerbations, even when including the adjudicated results of those patients treated with 
systemic antimicrobial agents but not meeting the protocol-defined signs or symptoms of an 
exacerbation. There was a significantly different incidence of hospitalizations between groups, 
which was lower in the LIS group compared to TIS.  Taken together these suggest a benefit in 
reduction of exacerbations from treatment with LIS (as has previously been shown for TIS [9]).   
There was a significant benefit in CFQ-R respiratory domain scores for patients treated 
with LIS compared to TIS.  However the patterns of response in this measure were unusual 
compared to other inhaled antibiotic studies.  In previous trials, mean improvements in CFQ-R 
respiratory domain scores during treatment waned when off therapy.  In this study, there was a 
general improvement in the CFQ-R score in the LIS group throughout the trial, whereas there 
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was little effect in the TIS group.  The explanation for these changes is not clear from our data, 
but may reflect the higher incidence of pulmonary exacerbations in the TIS treated group.   
One of the objectives of this study was to assess the safety of LIS compared to TIS, a 
therapy recommended in CFF and ECFS pulmonary guidelines [5, 6] and used over many years 
[23].  Overall the safety profile of LIS was similar to that of TIS.  The most notable difference in 
safety profiles was the higher incidence of taste distortion in patients receiving LIS, but this did 
not appear to have an impact on adherence to the regimen.  The	  inclusion	  criteria	  requiring	  a	  history	  
of	  TIS	  use	  offers	  a	  distinct	  advantage	  to	  TIS	  with	  respect	  to	  tolerability;	  patients	  who	  could	  not	  tolerate	  
TIS	  would	  not	  have	  participated.	  	  The	  previously	  reported	  rate	  of	  taste	  perversion	  for	  TIS	  was	  6.6%.	   
There are some limitations to the design and interpretation of this study.  The first is that 
the subjects were not blinded to treatment assignment because of differences in nebulizers used 
for LIS and TIS administration.  Despite an effort to reduce bias by attempting to keep the 
investigators blinded to treatment assignment, it was not possible to do this for study 
participants.  An active comparator was employed to study LIS because of the regulatory 
requirements to provide data on the noninferiority of LIS compared to the current standard of 
care for inhaled antibiotic therapy, TIS, over an extended period [16].  The regulatory 
requirements also necessitated the use of different delivery devices.  Whereas it might be 
perceived that the faster nebulizer might be preferable (i.e. favoring LIS), the choice of the 
nebulizer would not favor one drug over the other for the primary endpoint (i.e. FEV1).  It is 
acknowledged that patients, and possibly investigators, were aware of the treatment allocation in 
this study, and perhaps this may have influenced patient care and the assessment of subjective 
outcomes, such as the diagnosis and treatment of pulmonary exacerbations or patient quality of 
life.  Such biases might have an impact on the subjective endpoints, but we believe are unlikely 
to have affected objective endpoints (e.g. FEV1) in this study. 
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An additional limitation was that patients had a substantial treatment experience with 
inhaled tobramycin.  On the one hand this might favour the efficacy findings toward LIS, given 
the possibility of an attenuated response to TIS over time.  On the other hand, there was a likely 
selection for pre-existing TIS tolerance in this population, so we might expect fewer 
discontinuations in the TIS group.  However, we can also presume a considerable treatment 
experience with systemic fluoroquinolones in this population, given the substantial use of 
fluoroquinolones for the treatment of CF pulmonary exacerbations [24] and the levofloxacin 
susceptibilities of P. aeruginosa isolated from patients at baseline of this study (e-supplement 
Table 1). 
In conclusion, LIS has been shown to be non-inferior to TIS in people with CF 
chronically infected with P. aeruginosa.  There was no significant difference in time to first 
exacerbation between the two groups but there was significant improvement in quality of life 
assessed by CFQ-R respiratory scores, and a nominally significant reduction in respiratory-
associated hospitalizations.  No major safety concerns were seen in either group, and changes in 
airway microbiology were not dissimilar from what is observed in this patient population over 
the course of time.  LIS is as safe and as effective as the standard of care inhaled antibiotic, TIS, 
and offers an alternative class of antibiotics for use in the long term treatment of people with CF 
who are chronically infected with P. aeruginosa. 	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FIGURE LEGENDS 
Figure 1. Study design.  Patients were randomized 2:1 to receive LIS or TIS.  Three cycles of 28 
days BID treatment followed by 28 days off treatment were studied. 
 
Figure 2. Patient disposition 
 
Figure 3. Mean changes from Baseline in FEV1 % predicted and sputum P. aeruginosa density 
across the study by treatment group.  Gray boxes denote on-treatment periods. Solid circles and 
lines denote LIS, open circles and dashed lines denote TIS.  Bars represent standard errors.  
Upper panel: Mean relative change from baseline in FEV1% predicted. The LS mean for relative 
change in FEV1 percent predicted at Day 28 was in favour of LIS, but the difference was not 
statistically significant (2.24%, p=0.15). Lower Panel: Mean change from Baseline in log10 P. 
aeruginosa colony-forming units per gram sputum. 
Figure 4. Time-to-exacerbation by treatment group. Gray boxes denote on-treatment periods. 
Solid circles and lines denote LIS, open circles and dashed lines denote TIS.  Circles represent 
times at which patients were censored from the analysis. 
  
Table	  1:	  Demographics	  at	  baseline 
	   TIS	  (n=93)	   LIS	  (n=189)	  
Age,	  years	   	   	  
	  	  	  	  Mean	  (SD)	   28.8	  (10.9)	   28.1	  (8.96)	  
	  	  	  	  Median	   26.0	   27.0	  
	  	  	  	  >18	  years	   80	  (86.0%)	   163	  (86.2%)	  
Male	  Sex,	  N	  (%)	   56	  (60.2%)	   103	  (54.5%)	  
US	  Patients,	  N	  (%)	   63	  (67.7%)	   128	  (67.7%)	  
FEV1	  percent	  predicted	   	   	  
	  	  	  	  Mean	  (SD)	   53.2	  (15.7)	   54.8	  (17.0)	  
	  	  	  	  Median	   51.9	   54.0	  
	  	  	  	  <55,	  N	  (%)	   52	  (55.9%)	   100	  (52.9%)	  
BMI,	  kg/m2	   	   	  
	  	  	  	  Mean	  (SD)	   21.5	  (3.30)	   21.8	  (3.57)	  
	  	  	  	  Median	   20.8	   21.0	  
Inhaled	  antibiotic	  courses	  during	  previous	  year	  
	  	  	  	  Mean	  (SD)	   6.0	  (2.79)	   6.0	  (2.83)	  
	  	  	  	  Median	   5.0	   5.0	  
	  	  	  	  <2,	  N	  (%)	   3	  (3.2%)	   8	  (4.2%)	  
	  	  	  	  3,	  N	  (%)	   8	  (8.6%)	   23	  (12.2%)	  
	  	  	  	  4,	  N	  (%)	   17	  (18.3%)	   28	  (14.8%)	  
	  	  	  	  5,	  N	  (%)	   25	  (26.9%)	   44	  (23.3%)	  
	  	  	  	  >6,	  N	  (%)	   40	  (43.0%)	   85	  (45.0%)	  
Baseline	  pathogen	  isolation,	  N	  (%)	   	   	  
	  	  	  	  P	  aeruginosa	   86	  (92.5%)	   175	  (92.6%)	  
	  	  	  	  S	  aureus	   35	  (37.6%)	   96	  (50.8%)	  
	  	  	  	  Methicillin	  resistant	  S	  aureus	   12	  (12.9%)	   38	  (20.1%)	  
	  	  	  	  S	  maltophilia	   8	  (8.6%)	   20	  (10.6%)	  
	  	  	  	  A	  xylosoxidans	   6	  (6.5%)	   14	  (7.4%)	  
	  	  	  	  B	  cepacia	  complex	   1	  (1.1%)	   0	  (0.0%)	  
 
  
 Table	  2:	  Treatment	  Emergent	  Adverse	  Events	  (entire	  study)	  
	   TIS	  	  
N=90	  
LIS	  	  
N=182	  
System	  Organ	  Class	  /	  Preferred	  Term	   	   	  
Patients	  Reporting	  at	  Least	  1	  Adverse	  Event	   90	  (100.0%)	   180	  (98.9%)	  
Respiratory,	  thoracic	  and	  mediastinal	  disorders	  
	  	  	  Cough	   48	  (53.3%)	   106	  (58.2%)	  
	  	  	  Sputum	  increased	   40	  (44.4%)	   95	  (52.2%)	  
	  	  	  Respiratory	  tract	  congestion	   32	  (35.6%)	   68	  (37.4%)	  
	  	  	  Increased	  viscosity	  of	  bronchial	  secretion	   28	  (31.1%)	   59	  (32.4%)	  
	  	  	  Paranasal	  sinus	  hypersecretion	   18	  (20.0%)	   49	  (26.9%)	  
	  	  	  Haemoptysis	   18	  (20.0%)	   29	  (15.9%)	  
	  	  	  Sputum	  discoloured	   16	  (17.8%)	   26	  (14.3%)	  
	  	  	  Dyspnoea	  exertional	   15	  (16.7%)	   21	  (11.5%)	  
	  	  	  Rales	   8	  (8.9%)	   8	  (4.4%)	  
	  	  	  Dyspnoea	   5	  (5.6%)	   8	  (4.4%)	  
	  	  	  Oropharyngeal	  pain	   2	  (2.2%)	   12	  (6.6%)	  
	  	  	  Wheezing	   3	  (3.3%)	   5	  (2.7%)	  
	  	  	  Nasal	  congestion	   1	  (1.1%)	   8	  (4.4%)	  
	  	  	  Epistaxis	   5	  (5.6%)	   2	  (1.1%)	  
General	  disorders	  and	  administration	  site	  conditions	  
	  	  	  Disease	  progression	   59	  (65.6%)	   103	  (56.6%)	  
	  	  	  Fatigue	   25	  (27.8%)	   58	  (31.9%)	  
	  	  	  Exercise	  tolerance	  decreased	   14	  (15.6%)	   23	  (12.6%)	  
	  	  	  Pyrexia	   10	  (11.1%)	   17	  (9.3%)	  
Investigations	  
	  	  	  Weight	  decreased	   36	  (40.0%)	   57	  (31.3%)	  
	  	  	  Forced	  expiratory	  volume	  decreased	   15	  (16.7%)	   17	  (9.3%)	  
	  	  	  Pulmonary	  function	  test	  decreased	   8	  (8.9%)	   14	  (7.7%)	  
	  	  	  Blood	  glucose	  increased	   7	  (7.8%)	   4	  (2.2%)	  
Nervous	  system	  disorders	  
	  	  	  Dysgeusia	   0	  (0.0%)	   46	  (25.3%)	  
	  	  	  Sinus	  headache	   13	  (14.4%)	   35	  (19.2%)	  
	  	  	  Headache	   6	  (6.7%)	   11	  (6.0%)	  
Infections	  and	  infestations	  
	  	  	  Nasopharyngitis	   11	  (12.2%)	   17	  (9.3%)	  
	  	  	  Sinusitis	   8	  (8.9%)	   8	  (4.4%)	  
	  	  	  Upper	  respiratory	  tract	  infection	   5	  (5.6%)	   5	  (2.7%)	  
Gastrointestinal	  disorders	  
	  	  	  Abdominal	  pain	   7	  (7.8%)	   8	  (4.4%)	  
	  	  	  Nausea	   7	  (7.8%)	   11	  (6.0%)	  
Musculoskeletal	  and	  connective	  tissue	  disorders	  
	  	  	  Arthralgia	   5	  (5.6%)	   10	  (5.5%)	  
Metabolism	  and	  nutrition	  disorders	  
	  	  	  Decreased	  appetite	   16	  (17.8%)	   23	  (12.6%)	  
Skin	  and	  subcutaneous	  tissue	  disorders	  
	  	  	  Rash	   7	  (7.8%)	   6	  (3.3%)	  
 
 
